COLL EBITDA Growth
Collegium Pharmaceutical Inc · EBITDA Growth
COLL EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported36.53%period ending
COLL TTM EBITDA YoY % (-52.45% → 36.53%)
Year-over-year change
High-resolution chart · PNG
COLL ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 36.5344% | |
| 49.0779% | |
| 42.3776% | |
| 13.2657% | |
| -3.0682% | |
| -6.4086% | |
| 10.8242% | |
| 31.9525% | |
| 52.4885% | |
| 72.7485% | |
| 77.9106% | |
| 161.4105% | |
| 219.609% | |
| 256.3865% | |
| 100.2207% | |
| -25.8352% | |
| -47.8562% | |
| -58.945% | |
| -26.6553% | |
| 54.3065% | |
| 186.0816% | |
| 835.9747% | |
| 1,964.3602% | |
| 359.8105% | |
| 14.3093% | |
| -78.2992% | |
| -106.8872% | |
| -59.6246% | |
| 251.2772% | |
| 301.6596% | |
| 223.7495% | |
| 156.1348% | |
| 112.5906% | |
| 65.9113% | |
| 20.5029% | |
| -11.5743% | |
| -66.0847% | |
| -160.3747% | |
| -250.6455% | |
| -267.9396% | |
| -229.8953% | |
| -124.0072% | |
| -52.4518% |